Debut Plus

67.98

-5.52 -7.51%

17 Jul 2026

BSE Listed

Asston Pharmaceuticals Limited (544445)

Volume: 1,30,000Avg Vol 1W: 28,600Avg Vol 1M: 25,45552W Range:61.02126
Key Ratios
Checked 1h ago
Market Cap
Current Price₹67.98
Previous Close₹73.5
High / Low (52w)₹126 / ₹61.02
Volume1,30,000
Avg Vol (1W)28,600
Avg Vol (1M)25,455
Stock P/E
Book Value
Dividend Yield
ROE
ROA
Revenue (TTM)
Revenue Growth
Profit Margin
Total Debt
Shares Outstanding
Face Value
EPS (TTM)
P/B
Debt / Equity0.77
50 DMA₹77.14
200 DMA₹85.18
Day change-7.51%
Price Chart
67.98 44.96% · 1Y
124683.0L
2025-07-17
2026-07-17

20-day avg volume: 28K shares

Pros
  • Company is almost debt-free.
  • Revenue grew 62% YoY.
  • Net profit is growing year over year.
Profit & Loss (Annual)
MetricMar 2022Mar 2023Mar 2024Mar 2025
Revenue₹11 Cr₹7 Cr₹16 Cr₹26 Cr
EBITDA₹1 Cr₹2 Cr₹3 Cr₹6 Cr
Net Profit₹0 Cr₹1 Cr₹1 Cr₹4 Cr
EPS11.621.892.376.14
Balance Sheet
MetricMar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹9 Cr₹14 Cr₹20 Cr₹28 Cr
Total Liabilities₹9 Cr₹12 Cr₹14 Cr₹17 Cr
Equity₹1 Cr₹2 Cr₹6 Cr₹11 Cr
Total Debt
Cash Flow
MetricMar 2022Mar 2023Mar 2024Mar 2025
Operating₹-1 Cr₹0 Cr₹-4 Cr₹0 Cr
Investing₹0 Cr₹-1 Cr₹0 Cr₹1 Cr
Financing₹1 Cr₹1 Cr₹4 Cr₹-1 Cr
Free Cash Flow₹-1 Cr₹0 Cr₹-4 Cr₹0 Cr
Shareholding
Promoter 50.66% Institutions 1.91% Public 47.42%
Efficiency & Working Capital
ROCE
Interest Coverage6.3
Dividend Payout
Debtor Days358 d
Inventory Days10 d
Payable Days87 d
Cash Conversion Cycle281 d
Working Capital Days368 d
Shareholding Details

As of 2026-03-31

Promoter50.7%
FII1.9%
DII0%
Institutions1.9%
Public47.4%
Promoter Pledge0%
No. of Shareholders687
Shareholding Pattern

Quarterly — figures in %. Latest 5 quarters.

PeriodJan 2025Jun 2025Jul 2025Sept 2025Mar 2026
Promoters69.1%50.7%50.7%50.7%50.7%
FIIs0%9.7%9.7%6%1.9%
DIIs0%4.1%4.1%0%0%
Public30.9%35.6%35.6%43.3%47.4%
Promoter Pledge0%0%0%0%0%
No. of Shareholders104662662751687
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503
Major Shareholders (>1%)
NameCategoryStakeShares
Saili Jayaram MoreShareholding of Promoter and Promoter Group21.8%18,52,856
Ashish Narayan SakalkarShareholding of Promoter and Promoter Group21.8%18,52,856
Sachin Chandrakant BadakhShareholding of Promoter and Promoter Group7.1%6,06,768
Mahesh Vishnupant MulayPublic Shareholding2.9%2,48,056
Kuldip Singh RatheePublic Shareholding2.4%2,00,000
Minerva Ventures FundPublic Shareholding1.9%1,63,000
Vrushali Yogesh SupekarPublic Shareholding1.5%1,24,466
Dilip Rameshchandra JagadPublic Shareholding1.3%1,06,672
Promoter Pledges
HolderPledged Shares% of HoldingAs of
Saili Jayaram More00%2026-03-31
Ashish Narayan Sakalkar00%2026-03-31
Sachin Chandrakant Badakh00%2026-03-31
Minerva Ventures Fund00%2026-03-31
Kuldip Singh Rathee00%2026-03-31
Vrushali Yogesh Supekar00%2026-03-31
Mahesh Vishnupant Mulay00%2026-03-31
Dilip Rameshchandra Jagad00%2026-03-31
Saili Jayaram More00%2025-09-30
Ashish Narayan Sakalkar00%2025-09-30
Sachin Chandrakant Badakh00%2025-09-30
Minerva Ventures Fund00%2025-09-30
Board of Directors
NameDesignationYear
Ashish Narayan SakalkarManaging Director2025
Saili Jayaram MoreWhole Time Director & CEO2025
Sachin Chandrakant BadakhNon Executive Director2025
Rishabh Kumar JainIndependent Non Exe. Director2025
Vijaya ShahpurkarIndependent Non Exe. Director2025
Vandana MishraCompany Sec. & Compli. Officer2025
Yashvardhan TupeAdditional Director2025
Sandip SharmaAdditional Director2025
Segments — Geography
RegionRevenueShare
Export₹22 Cr86.2%
Domestic₹3 Cr13.8%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹101266
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2025010304
2025000202
2025010001
Company Information
Incorporated2019
AuditorDoshi Doshi & Co
Investor Email[email protected]
🌐 www.asstonpharmaceuticals.com

📍 4th Flr Office No.A-431 Balaji, Bhavan Plot No.42A Sec-11 CBD, Mumbai, Maharashtra, 400614

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search